These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 24748129)

  • 1. Significance of allelic percentage of BRAF c.1799T > A (V600E) mutation in papillary thyroid carcinoma.
    Cheng SP; Hsu YC; Liu CL; Liu TP; Chien MN; Wang TY; Lee JJ
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S619-26. PubMed ID: 24748129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.
    Gandolfi G; Sancisi V; Torricelli F; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A
    J Clin Endocrinol Metab; 2013 May; 98(5):E934-42. PubMed ID: 23533235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome.
    Guerra A; Fugazzola L; Marotta V; Cirillo M; Rossi S; Cirello V; Forno I; Moccia T; Budillon A; Vitale M
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2333-40. PubMed ID: 22508706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of BRAF V600E alleles predicts papillary thyroid cancer progression.
    Kim MH; Bae JS; Lim DJ; Lee H; Jeon SR; Park GS; Jung CK
    Endocr Relat Cancer; 2014; 21(6):891-902. PubMed ID: 25266729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
    Guerra A; Zeppa P; Bifulco M; Vitale M
    Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of BRAFV600E mutation with clinicopathological features of papillary thyroid carcinoma: a study on a Chinese population.
    Liu S; Zhang B; Zhao Y; Chen P; Ji M; Hou P; Shi B
    Int J Clin Exp Pathol; 2014; 7(10):6922-8. PubMed ID: 25400776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
    Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
    Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.
    Kurtulmus N; Duren M; Ince U; Cengiz Yakicier M; Peker O; Aydın O; Altiok E; Giray S; Azizlerli H
    Endocrine; 2012 Oct; 42(2):404-10. PubMed ID: 22426956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.
    Gu LQ; Li FY; Zhao L; Liu Y; Zang XX; Wang TX; Chen HP; Ning G; Zhao YJ
    Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increase in Papillary Thyroid Cancer Incidence Is Accompanied by Changes in the Frequency of the BRAF V600E Mutation: A Single-Institution Study.
    Kowalska A; Walczyk A; Kowalik A; Pałyga I; Trybek T; Kopczyński J; Kajor M; Chrapek M; Pięciak L; Chłopek M; Góźdź S; Kamiński G
    Thyroid; 2016 Apr; 26(4):543-51. PubMed ID: 26889698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
    Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
    World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of BRAF c.1799T > A (p.V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma.
    Zhao H; Zhang ZH; Zhou B; Xiao T; Pan QJ; Guo HQ
    Diagn Cytopathol; 2015 Oct; 43(10):786-90. PubMed ID: 26152656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas.
    Kim BH; Kim IJ; Lee BJ; Lee JC; Kim IS; Kim SJ; Kim WJ; Jeon YK; Kim SS; Kim YK
    Yonsei Med J; 2015 May; 56(3):634-40. PubMed ID: 25837167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma.
    Guerra A; Sapio MR; Marotta V; Campanile E; Rossi S; Forno I; Fugazzola L; Budillon A; Moccia T; Fenzi G; Vitale M
    J Clin Endocrinol Metab; 2012 Feb; 97(2):517-24. PubMed ID: 22170714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
    Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
    Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas.
    de Biase D; Cesari V; Visani M; Casadei GP; Cremonini N; Gandolfi G; Sancisi V; Ragazzi M; Pession A; Ciarrocchi A; Tallini G
    J Clin Endocrinol Metab; 2014 Aug; 99(8):E1530-8. PubMed ID: 24780046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
    Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
    JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of the extent of BRAF
    Liu L; Chang JW; Jung SN; Park HS; Oh T; Lim YC; Koo BS
    Oral Oncol; 2016 Nov; 62():72-77. PubMed ID: 27865374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
    Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O
    Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAFV600E mutation in fine-needle aspiration aspirates: Association with poorer prognostic factors in larger papillary thyroid carcinomas.
    Lee JI; Jang HW; Kim SW; Kim JW; Oh YL; Chung JH
    Head Neck; 2013 Apr; 35(4):548-53. PubMed ID: 22488961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.